Breaking News

Rapid Configurability System to Investigate SARS-CoV-2 Variants

January 18, 2021 • 2:40 pm CST
(Precision Vaccinations News)

Massachusetts based LexaGene Holdings, Inc. announced that it had initiated a program that uses the rapid configurability of the MiQLab™ system to investigate novel variants of SARS-CoV-2, the pathogen that causes COVID-19. LexaGene’s MiQLab can be easily configured to run tests for both coronavirus detection and strain identification as it is capable of screening for up to 27 genetic targets at once.

LexaGene stated in a press statement issued on January 13, 2021; it is pursuing U.S. FDA authorization for COVID-19 testing using assays that are predicted to detect >99.9% of the strains circulating today based on published sequences, including the UK and South African coronavirus variants. To date, there is no FDA approved device that is designed for point-of-care usage and is open-access, says the company.

Dr. Jack Regan, LexaGene’s CEO, said, "Once a pathogen emerges or mutates, the MiQLab system is designed to quickly onboard new tests to detect a desired target, which would speed up timelines for point-of-care testing. Detecting these variants quickly inside hospitals, clinics, and other testing locations maximizes the chances of successfully containing these new threats.”

Our Trust Standards: Medical Advisory Committee

Share